Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy

Journal of the Formosan Medical Association

Volumn 115, Issue 1, 2016, Pages 11-18

  Peng, Lei ^a   Wei, Shi Yao ^a   Li, Lei Ting ^a   He, Yi Xin ^a   Li, Bing ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cyclophosphamide; Idiopathic membranous nephropathy; Mycophenolate mofetil; Proteinuria; Tacrolimus

Indexed keywords

AMINOTRANSFERASE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; MYCOPHENOLATE MOFETIL; SERUM ALBUMIN; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; ADVERSE DRUG REACTION; ALBUMIN BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG DOSE REDUCTION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND TREMOR; HIGH RISK PATIENT; HUMAN; HYPOALBUMINEMIA; IDIOPATHIC DISEASE; IDIOPATHIC MEMBRANOUS NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; CHINA; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; GLOMERULONEPHRITIS, MEMBRANOUS; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; CHINA; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; PROTEINURIA; REMISSION INDUCTION; TACROLIMUS; TREATMENT OUTCOME;

EID: 84958755014     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2015.07.021     Document Type: Article

References (39)

1. Naumovic R., Pavlovic S., Stojkovic D., Basta-Jovanovic G., Nesic V. Renal biopsy registry from a single centre in Serbia: 20 years of experience. Nephrol Dial Transplant 2009, 24:877-885.
2. Li L.S., Liu Z.H. Epidemiologic data of renal diseases from a single unit in china: Analysis based on 13,519 renal biopsies. Kidney Int 2004, 66:920-923.
3. Ronco P., Debiec H. Pathogenesis of membranous nephropathy: Recent advances and future challenges. Nat Rev Nephrol 2012, 8:203-213.
4. Lai W.L., Yeh T.H., Chen P.M., Chan C.K., Chiang W.C., Chen Y.M., et al. Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment. J Formos Med Assoc 2015, 114:102-111.
5. Hogan J., Mohan P., Appel G.B. Diagnostic tests and treatment options in glomerular disease. Am J Kidney Dis 2014, 63:656-666.
6. Radhakrishnan J., Cattran D.C. The KDIGO practice guideline on glomerulonephritis: Reading between the (guide)lines-application to the individual patient. Kidney Int 2012, 82:840-856.
7. Ponticelli C. Membranous nephropathy. J Nephrol 2007, 20:268-287.
8. Jha V., Ganguli A., Saha T.K., Kohli H.S., Sud K., Gupta K.L., et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007, 18:1899-1904.
9. Faurschou M., Sorensen I.J., Mellemkjaer L., Loft A.G., Thomsen B.S., Tvede N., et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008, 35:100-105.
10. Ponticelli C., Altieri P., Scolari F., Passerini P., Roccatello D., Cesana B., et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998, 9:444-450.
11. Yuan J., Fang W., Zhang W., Ni Z., Qian J. Treatment of nephrotic idiopathic membranous nephropathy with monthly i.V. Pulse cyclophosphamide and oral steroids: a single centre's retrospective study. Nephrology (Carlton) 2011, 16:440-445.
12. Dussol B., Morange S., Burtey S., Indreies M., Cassuto E., Mourad G., et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis 2008, 52:699-705.
13. Chan T.M., Lin A.W., Tang S.C., Qian J.Q., Lam M.F., Ho Y.W., et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 2007, 12:576-581.
14. Praga M., Barrio V., Juarez G.F., Luno J. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 2007, 71:924-930.
15. Xu J., Zhang W., Xu Y., Shen P., Ren H., Wang W., et al. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial. Contrib Nephrol 2013, 181:152-162.
16. He L., Peng Y., Liu H., Liu Y., Yuan S., Liu F., et al. Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids. J Nephrol 2013, 26:564-571.
17. Chen M., Li H., Li X.Y., Lu F.M., Ni Z.H., Xu F.F., et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci 2010, 339:233-238.
18. Li X., Lv R., He Q., Li H., Du X., Lin W., et al. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria. J Nephrol 2008, 21:584-591.
19. Faul C., Donnelly M., Merscher-Gomez S., Chang Y.H., Franz S., Delfgaauw J., et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008, 14:931-938.
20. Peng L., Ma J., Cui R., Chen X., Wei S.Y., Wei Q., et al. The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4. PLoS One 2014, 9:e106164.
21. Mathieson P.W., Turner A.N., Maidment C.G., Evans D.J., Rees A.J. Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet 1988, 2:869-872.
22. Torres A., Dominguez-Gil B., Carreno A., Hernandez E., Morales E., Segura J., et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int 2002, 61:219-227.
23. Cattran D.C., Pei Y., Greenwood C.M., Ponticelli C., Passerini P., Honkanen E. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997, 51:901-907.
24. Ponticelli C., Passerini P. Management of idiopathic membranous nephropathy. Expert Opin Pharmacother 2010, 11:2163-2175.
25. Hofstra J.M., Branten A.J., Wirtz J.J., Noordzij T.C., Du Buf-Vereijken P.W., Wetzels J.F. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrol Dial Transplant 2010, 25:129-136.
26. Senthil Nayagam L., Ganguli A., Rathi M., Kohli H.S., Gupta K.L., Joshi K., et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 2008, 23:1926-1930.
27. Sola R., Diaz J.M., Guirado L., Sainz Z., Gich I., Picazo M., et al. Tacrolimus in induction immunosuppressive treatment in renal transplantation: comparison with cyclosporine. Transplant Proc 2003, 35:1699-1700.
28. Yuan H., Liu N., Sun G.D., Jia Y., Luo P., Miao L.N. Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome. Pharmacology 2013, 91:259-266.
29. Laluck B.J., Cattran D.C. Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis 1999, 33:1026-1032.
30. Troyanov S., Wall C.A., Miller J.A., Scholey J.W., Cattran D.C. Toronto Glomerulonephritis Registry G. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004, 66:1199-1205.
31. Borrego J., Mazuecos A., Gentil M.A., Cabello M., Rodriguez A., Osuna A., et al. Proteinuria as a predictive factor in the evolution of kidney transplantation. Transplant Proc 2013, 45:3627-3629.
32. Kang S.H., Cho K.H., Park J.W., Yoon K.W., Do J.Y. Proteinuria as a risk factor for decline in residual renal function in non-diabetic peritoneal dialysis patients. Kidney Blood Press Res 2013, 37:199-210.
33. Massella L., Muda A.O., Legato A., Di Zazzo G., Giannakakis K., Emma F. Cyclosporine a treatment in patients with alport syndrome: a single-center experience. Pediatr Nephrol 2010, 25:1269-1275.
34. Yap D.Y., Yu X., Chen X.M., Lu F., Chen N., Li X.W., et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton) 2012, 17:352-357.
35. Sinha M.D., Macleod R., Rigby E., Clark A.G. Treatment of severe steroid-dependent nephrotic syndrome (sdns) in children with tacrolimus. Nephrol Dial Transplant 2006, 21:1848-1854.
36. Chamienia A., Biedunkiewicz B., Krol E., Debska-Slizien A., Rutkowski B. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus. Transplant Proc 2006, 38:81-85.
37. Ankivell B.J., Borrows R.J., Fung C.L., O'connell P.J., Chapman J.R., Allen R.D. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004, 78:557-565.
38. Tse K.C., Lam M.F., Tang S.C., Tang C.S., Chan T.M. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 2007, 16:46-51.
39. Alexopoulos E., Stangou M., Papagianni A., Pantzaki A., Papadimitriou M. Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 2000, 15:1348-1356.